Sign In
Buy IVBXF
$10.24
-0.190 (-1.83%)
At Close: Jun 03, 2026
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
08:00pm, Monday, 15'th Apr 2024
SAN FRANCISCO and SUZHOU, China , April 15, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercia
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
08:00pm, Sunday, 07'th Apr 2024
ROCKVILLE, Md. and SUZHOU, China , April 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial
ROCKVILLE, Md. and SUZHOU, China , March 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerc
Innovent Announces 2023 Annual Results and Business Updates
07:41am, Wednesday, 20'th Mar 2024
A transformative year of strong performance and material innovation progress ROCKVILLE, M.D. and SUZHOU, China , March 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a wor
ROCKVILLIE, Md. and SUZHOU, China , March 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commer
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
08:00pm, Monday, 11'th Mar 2024
ROCKVILLE, Md. and SUZHOU, China , March 11, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerci
ROCKVILLIE, Md. and SUZHOU, China , March 6, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerci
ROCKVILLE, Md. and SUZHOU, China , March 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerci
NEW YORK & SUZHOU, China--(BUSINESS WIRE)--AnHeart Therapeutics & Innovent announce China's NMPA has accepted second NDA for taletrectinib for first-line treatment of ROS1-positive lung cancer.
